Levosimendan Administration and Outcome in Cardiac Surgery
NCT ID: NCT02275013
Last Updated: 2014-10-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
159 participants
OBSERVATIONAL
2006-01-31
2013-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Impact of Levosimendan Preconditioning on Critical Care and In-hospital Lengths of Stay After Cardiac Surgery With Bypass Surgery
NCT05685537
Effect Levosimendan Administration on Postoperative NT-proBNP in Cardiac Risk Patients
NCT04329624
Levosimendan in High Risk Patients Undergoing Cardiac Surgery
NCT00994825
Vasoactive-inotropic Support and Levosimendan Use After Lung Transplantation
NCT05702333
Management of the Patient at High Risk Hemorrhagic in Cardiac Surgery by Monitoring Viscoelastic Hemostasis.
NCT06550505
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Early
Levosimendan administration within first hour of post-operative ICU admission
Levosimendan
Late
Levosimendan administration within 24 hours of post-operative ICU admission but after first hour
Levosimendan
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Levosimendan
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* levosimendan administration within 24 hours of postoperative ICU admission
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Charite University, Berlin, Germany
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Michael Sander
Univ-Prof. Dr. med.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Charité University Medicine
Berlin, State of Berlin, Germany
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Treskatsch S, Balzer F, Geyer T, Spies CD, Kastrup M, Grubitzsch H, Wernecke KD, Erb JM, Braun JP, Sander M. Early levosimendan administration is associated with decreased mortality after cardiac surgery. J Crit Care. 2015 Aug;30(4):859.e1-6. doi: 10.1016/j.jcrc.2015.03.008. Epub 2015 Mar 13.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ea1-044-13b
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.